Intuitive Surgical, Inc. (NASDAQ:ISRG) Director Sells $2,626,191.00 in Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) Director Amal M. Johnson sold 4,635 shares of Intuitive Surgical stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $566.60, for a total transaction of $2,626,191.00. Following the completion of the transaction, the director now directly owns 12,275 shares of the company’s stock, valued at approximately $6,955,015. This trade represents a 27.41 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Intuitive Surgical Price Performance

Shares of NASDAQ:ISRG opened at $580.18 on Friday. The firm has a 50 day simple moving average of $549.32 and a 200 day simple moving average of $507.50. The company has a market cap of $206.65 billion, a price-to-earnings ratio of 93.28, a PEG ratio of 5.19 and a beta of 1.39. Intuitive Surgical, Inc. has a one year low of $364.17 and a one year high of $616.00.

Institutional Investors Weigh In On Intuitive Surgical

Several hedge funds have recently modified their holdings of ISRG. Berbice Capital Management LLC acquired a new position in Intuitive Surgical in the 4th quarter worth about $26,000. Godsey & Gibb Inc. increased its stake in shares of Intuitive Surgical by 140.0% in the third quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 35 shares during the period. MidAtlantic Capital Management Inc. bought a new position in Intuitive Surgical in the 3rd quarter valued at approximately $33,000. Decker Retirement Planning Inc. bought a new position in Intuitive Surgical in the 4th quarter valued at approximately $36,000. Finally, Capital Performance Advisors LLP bought a new stake in Intuitive Surgical during the 3rd quarter worth approximately $38,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Wall Street Analysts Forecast Growth

ISRG has been the subject of a number of research analyst reports. Truist Financial lifted their price target on Intuitive Surgical from $640.00 to $666.00 and gave the stock a “buy” rating in a report on Friday, January 24th. Erste Group Bank raised Intuitive Surgical from a “hold” rating to a “buy” rating in a report on Tuesday, November 19th. Bernstein Bank raised their price target on Intuitive Surgical from $655.00 to $700.00 and gave the company an “overweight” rating in a report on Monday. Wells Fargo & Company lifted their price objective on shares of Intuitive Surgical from $630.00 to $687.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Intuitive Surgical from $575.00 to $675.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, Intuitive Surgical currently has an average rating of “Moderate Buy” and a consensus target price of $613.10.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.